MARKET

CANF

CANF

Can Fite Biophar
AMEX
2.260
+0.080
+3.67%
Closed 16:00 03/27 EDT
OPEN
2.233
PREV CLOSE
2.180
HIGH
2.260
LOW
2.210
VOLUME
11.26K
TURNOVER
0
52 WEEK HIGH
3.330
52 WEEK LOW
1.520
MARKET CAP
13.66M
P/E (TTM)
-0.8694
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CANF last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at CANF last week (0311-0315)?
Weekly Report · 03/18 09:35
Can Fite Biophar: Report of foreign issuer
Press release · 03/11 12:03
Weekly Report: what happened at CANF last week (0304-0308)?
Weekly Report · 03/11 09:34
Weekly Report: what happened at CANF last week (0226-0301)?
Weekly Report · 03/04 09:35
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Can-Fite BioPharma Ltd. Has received a patent for its drug for the reduction of liver fat in patients with NASH. The drug, Namodenoson, reduced liver fat content and showed anti-inflammatory effects in a Phase IIa study. The company's other drug, Piclidenoson, is being developed for the treatment of psoriasis.
Barchart · 02/28 06:00
Weekly Report: what happened at CANF last week (0219-0223)?
Weekly Report · 02/26 09:39
Weekly Report: what happened at CANF last week (0212-0216)?
Weekly Report · 02/19 09:39
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.